SpringBig Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SpringBig Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.83M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $24.65M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $28.05M | Mar 28, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $28.05M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $26.63M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $7.23M | Mar 28, 2023 |
| FY2022 | Jun 30, 2022 | $6.45M | Mar 28, 2023 |
| FY2022 | Mar 31, 2022 | $6.17M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $23.36M | Mar 28, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.99M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $17.99M | Mar 27, 2026 |
| FY2024 | Sep 30, 2024 | $4.44M | Mar 28, 2025 |
| FY2024 | Jun 30, 2024 | $4.70M | Mar 28, 2025 |
| FY2024 | Mar 31, 2024 | $4.68M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $21.56M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $19.93M | Apr 1, 2024 |
| FY2022 | Sep 30, 2022 | $5.54M | Mar 28, 2023 |
| FY2022 | Jun 30, 2022 | $4.59M | Mar 28, 2023 |
| FY2022 | Mar 31, 2022 | $4.52M | Mar 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.25M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.88M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($10.23M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($13.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.75M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($5.1K) | Apr 26, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.73M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($600.0K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.34M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($16.30M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.53M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($5.1K) | Apr 26, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.76M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.90M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $8.01M | Mar 28, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $361.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($953.0K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.98M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($14.52M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($7.88M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($64) | Apr 26, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $64.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $351.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $154.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $252.0K | Mar 28, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.63M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.83M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $5.11M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.66M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.04M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $602.8K | Apr 26, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.12M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $16.60M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $13.78M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $13.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.58M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $582.9K | Apr 26, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.49M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($9.77M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | ($8.67M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | ($3.63M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $4.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $9.53M | Mar 28, 2023 |
| FY2021 | Jan 23, 2020 | $0 | Apr 26, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.0K | Mar 27, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.69M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($38.44M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($36.57M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($26.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.23M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($5.1K) | Apr 26, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.18M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $331.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.55M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.23M | Mar 28, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $8.36M | Mar 28, 2025 |
| FY2022 | Sep 30, 2022 | $9.31M | Mar 28, 2023 |
| FY2022 | Jun 30, 2022 | $9.15M | Mar 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.55M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 46.35M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 45.34M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 26.66M | Apr 1, 2024 |
| FY2023 | Jun 14, 2022 | 25.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 17.86M | Mar 28, 2023 |